Lyell Immunopharma, Inc. (LYEL)
Largest Insider Buys in Sector
LYEL Stock Price History Chart
LYEL Stock Performance
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that …
Insider Activity of Lyell Immunopharma, Inc.
Over the last 12 months, insiders at Lyell Immunopharma, Inc. have bought $0 and sold $0 worth of Lyell Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Lyell Immunopharma, Inc. have bought $300,016 and sold $132,286 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,648 shares for transaction amount of $300,016 was made by FRIEDMAN CATHY (director) on 2021‑06‑21.
List of Insider Buy and Sell Transactions, Lyell Immunopharma, Inc.
| 2023-08-15 | Sale | director | 58,020 0.0231% | $2.28 | $132,286 | -10.26% | ||
| 2021-06-21 | director | 17,648 0.0422% | $17.00 | $300,016 | -50.33% |
Insider Historical Profitability
| FRIEDMAN CATHY | director | 17648 0.006% | $0.66 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Mwg Management Ltd | $44.96M | 7.91 | 20.16M | 0% | +$0 | 33.29 | |
| Orland Properties Ltd | $33.66M | 5.92 | 15.09M | 0% | +$0 | 19.04 | |
| BlackRock | $30.98M | 5.45 | 13.89M | -2.86% | -$913,392.41 | <0.01 | |
| The Vanguard Group | $29.86M | 5.25 | 13.39M | -1.58% | -$480,792.46 | <0.01 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $18.56M | 3.27 | 8.32M | 0% | +$0 | 10.78 |